Top Story

Autologous stem cell transplantation improves outcomes in refractory myeloma

July 20, 2017

High-dose therapy with autologous hematopoietic stem cell transplantation appeared safe and effective among patients with refractory multiple myeloma, according to a retrospective analysis published in Cancer.

Patients with multiple myeloma who fail to respond to induction therapy or who become refractory after initial response demonstrate poor outcomes. This especially includes patients who are double refractory, or refractory to both proteasome inhibitors and immunomodulatory agents.

NewsMeeting News

Maintenance pembrolizumab benefits certain patients with small cell lung cancer

July 19, 2017
CHICAGO – Improvements in OS, but not PFS, indicate that maintenance treatment with pembrolizumab may benefit a subset of patients with small cell lung cancer, and…
Meeting NewsVideo

VIDEO: Genomic risk system may help treat prostate cancer

July 19, 2017
CHICAGO — The use of a genomic classifier in combination with clinicopathologic variables may provide a valuable prognostic system for distant metastases and…

Beat AML Master Trial to expand with more institutions, targeted therapies

July 19, 2017
The Leukemia & Lymphoma Society plans to expand its Beat AML Master Trial with additional cancer centers, patients and investigational targeted therapies. The Beat…

ASCO presents value-based solutions to promote affordability, preserve innovation of cancer drugs

July 19, 2017
ASCO today issued a position statement that proposes a wide range of cost-cutting strategies that can be tested to help lower drug costs based on a standard definition…
More News Headlines »

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

This activity is supported by an educational grant from Merck & Co, Inc.

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised…
More »
Meeting News

VIDEO: Results of LATITUDE trial reinforce long-hypothesized theory in prostate cancer treatment

June 21, 2017
More »
Resource Centers
Biosimilars in the US

Biosimilars in the US


The Patient with Invasive Breast Cancer

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with invasive breast cancer.
More »
Current Issues
View the Current Issue
HemOnc Today